Richard L. Cassin Publisher and Editor
Andy Spalding Senior Editor
Jessica Tillipman Senior Editor
Elizabeth K. Spahn Contributing Editor
Eric Carlson Contributing Editor
Benjamin Kessler Contributing Editor
Michael Kuria Contributing Editor
Thomas Fox Contributing Editor
Philip Fitzgerald Contributing Editor
Marc Alain Bohn Contributing Editor
Michael Scher Contributing Editor
Bill Waite Contributing Editor
Shruti J. Shah Contributing Editor
Dr. Henry Wong Contributing Editor
Russell A. Stamets Contributing Editor
Mark R. Friedman Contributing Editor
Andrew Reichardt Editorial Intern
Richard L. Cassin | Thursday, March 14, 2013 at 7:28AM 
ProPublica ran an exposé this week about big bucks for doctors who promote products for drug companies.
Benjamin Kessler | Monday, February 4, 2013 at 6:02AM 
Authorities in Guangdong Province are responding with special seriousness to industry-wide anti-corruption regulations issued by the Ministry of Health (MOH) in July 2012.
Marc Alain Bohn | Thursday, January 24, 2013 at 6:18AM 
In the prior post, I explained why a broad definition of 'declinations' is needed to overcome a lack transparency by the DOJ and SEC when tracking agency decisions conclude FCPA investigations without pursuing enforcement actions.
Richard L. Cassin | Friday, January 4, 2013 at 4:18AM 
On his great Conflict of Interest Blog, Jeff Kaplan posted the ten biggest U.S. corporate criminal fines of all time.
Richard L. Cassin | Wednesday, January 2, 2013 at 4:32AM 
Twelve companies settled FCPA enforcement actions in 2012 by paying a total of $259.4 million.
Richard L. Cassin | Monday, October 1, 2012 at 3:08AM 
During the quarter just ended, there were five corporate FCPA enforcement actions, one enforcement against an individual by the SEC, four criminal sentencings of individuals, and three and a half corporate declinations.
Here's what happened:
Richard L. Cassin | Tuesday, August 21, 2012 at 12:28AM Prague to Perth is more than 15 hours of flying time. Stops in Hong Kong to break up the trip are common, and for some people, necessary. But don't say that to the SEC.
Richard L. Cassin | Wednesday, August 8, 2012 at 8:02AM We haven't had to update our list of corporate FCPA cases with the biggest disgorgements since March 2011. But now we do, thanks to Pfizer.
Richard L. Cassin | Tuesday, August 7, 2012 at 12:32PM The SEC said Pfizer's employees and agents paid bribes in Bulgaria, China, Croatia, Czech Republic, Italy, Kazakhstan, Russia, and Serbia. Improper payments went to foreign officials 'to obtain regulatory and formulary approvals, sales, and increased prescriptions for the company’s pharmaceutical products.'
Richard L. Cassin | Thursday, July 12, 2012 at 11:18AM In November 2011, Pfizer said: 'We anticipate entering into and announcing final [FCPA settlement] agreements in the fourth quarter.' What happened?
